Respiratory
COPD (chronic Obstructive Pulmonary Disease)
2
Pipeline Programs↗
11
Active Trials↗
6
Companies Involved↗
COPD (Chronic Obstructive Pulmonary Disease) is an early-stage landscape with 2 programs across 6 companies. The most active players are Eli Lilly, Haisco Pharmaceutical Group Co., Ltd., AstraZeneca. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Approved
No programs
Analysis
Trial Status
11
clinical trials
Not yet recruiting5 · 45%
Active, not recruiting4 · 36%
Recruiting2 · 18%
Clinical Trials
Trial Activity
11 trials
Self-management Digital Intervention to Promote Physical Activity in People Living With Chronic Obstructive Pulmonary Disease: a Pilot Randomized Controlled Trial Study Protocol
Active, not recruiting·IInstitut et Haute Ecole de la Santé la Source·Preclinical·NCT07262229·23 enrolled
Effects of Vibrating Mesh Nebulisation in Patients With COPD During Non-invasive Ventilation (VMN-NIV)
Active, not recruiting·GGuy's and St Thomas' NHS Foundation Trust·Preclinical·NCT06884228·12 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)